<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-75997</identifier>
<setSpec>0213-4853</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Onset of dopaminergic therapy in Parkinson&#146;s disease: six good reasons not to delay it</dc:title>
<dc:description xml:lang="en">Determining the point at which drug therapy with adopaminergic agent should begin in a patient with earlyParkinson disease is controversial. The current trend favorsnot indicating any drug until functional disability ispresent. However, the evolution demonstrated by patientsincluded in different clinical trials indicates thatdelaying dopaminergic treatment is associated withworst outcome. In addition, there are other experimentaland clinical data that support this idea. On the other sideof the argument is the possibility that early use of drugsmay inducing adverse effects in non-disabled patients (AU)</dc:description>
<dc:creator>Linazasoro, G</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El momento del inicio de la terapia dopaminérgica en laenfermedad de Parkinson es controvertido. La tendencia esa no indicar ningún fármaco hasta que exista incapacidadfuncional. Sin embargo, la evolución mostrada por pacientesincluidos en diversos ensayos clínicos indica que el retrasodel tratamiento dopaminérgico se asocia con una peorevolución clínica. Además existen otras evidencias experimentalesy clínicas que apoyan esta idea. En el otro lado dela balanza debe colocarse la posibilidad de provocar efectosadversos en pacientes no incapacitados con el uso precoz demedicamentos (AU)</dc:description>
<dc:source>Neurologia;23(5): 209-305, jun. 2008.</dc:source>
<dc:identifier>ibc-75997</dc:identifier>
<dc:title xml:lang="es">Inicio de la terapia dopaminérgica en la enfermedad de Parkinson: seis buenas razones para no retrasarlo</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d26532</dc:subject>
<dc:subject>^d23987^s22018</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23987^s22078</dc:subject>
<dc:subject>^d23987^s22020</dc:subject>
<dc:subject>^d10489^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>200806</dc:date>
</metadata>
</record>
</ibecs-document>
